Ferric carboxymaltose
- Generic Name
- Ferric carboxymaltose
- Brand Names
- Injectafer
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9007-72-1
- Unique Ingredient Identifier
- 6897GXD6OE
- Background
Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
- Indication
Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 97
- Registration Number
- NCT03466983
- Locations
- 🇩🇰
Pharmacosmos Investigational Site, Silkeborg, Denmark
A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 71
- Registration Number
- NCT03399084
- Locations
- 🇺🇸
Sandoz Investigative Site, Miami, Florida, United States
Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Hasselt University
- Target Recruit Count
- 75
- Registration Number
- NCT03380520
- Locations
- 🇧🇪
Pieter Martens, Genk, Limburg, Belgium
Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue
- Conditions
- Interventions
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Albina Nowak, MD
- Target Recruit Count
- 20
- Registration Number
- NCT03305705
- Locations
- 🇨🇭
University Hospital Zurich, Zürich, Switzerland
Preoperative Intravenous Iron Infusion to Reduce Post-surgical Complications: a Pilot Randomised Control Trial
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03295851
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 123
- Registration Number
- NCT03238911
- Locations
- 🇺🇸
Pharmacosmos Investigational Site, Leesburg, Virginia, United States
🇺🇸Pharmacosmos Investigational Site 2, Miami, Florida, United States
🇺🇸Pharmacosmos Investigational Site 1, Miami, Florida, United States
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 122
- Registration Number
- NCT03237065
- Locations
- 🇺🇸
Pharmacosmos Investigational Site, Winston-Salem, North Carolina, United States
🇺🇸Pharmacosmos investigational Site, Flint, Michigan, United States
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
- Conditions
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 20
- Registration Number
- NCT03218384
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Prof Gérard WAEBER
- Target Recruit Count
- 32
- Registration Number
- NCT03191201
- Locations
- 🇨🇭
Policlinique Médicale Universitaire, Lausanne, Vaud, Switzerland
Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency
- Conditions
- Interventions
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 23
- Registration Number
- NCT03079518
- Locations
- 🇩🇪
Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine at the University Hospital, RWTH Aachen, Aachen, NRW, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.